Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.
By L. Saltz, N. Meropol, P. Loehrer, M. Needle, J. Kopit, R. Mayer. Journal of Clinical Oncology, 2004
1,747 citations recorded by the source corpus.
Subfields: Oncology
View Paper: https://www.semanticscholar.org/paper/1f49ce2d0bbcfab5b9d8c1aad04cda2447f437a3
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- Protein therapeutics: a summary and pharmacological classification (2008, background): “The therapeutic synergy between irinotecan and cetuximab may be due to the fact that both drugs inhibit the same EGFR signalling pathway, with one drug (cetuximab) inhibiting the initiation of the pathway and the other drug (irinotecan) inhibiting a target downstream in the pathwa”
- KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. (2006, background): “The chimeric IgG1 monoclonal antibody cetuximab has been proven efficient in irinotecan-resistant metastatic colorectal cancer expressing the EGFR by immunohistochemistry, with response rates ranging between 8.8% when used in monotherapy and 22.9% when combined with irinotecan (2, 3 ). However, the”
- Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. (2005, background): “Cetuximab, a monoclonal antibody against the epithelial growth factor receptor (EGFR), induces responses in 10% and 23% of patients with irinotecan-refractory colorectal cancer as monotherapy [21–23] or in combination with irinotecan [22, 24], respectively.”
- Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. (2005, background): “Thirdly, there is growing evidence for a possible correlation between tumour response and the presence or extent of skin rash as demonstrated with cetuximab [2, 3 , 10, 36], panitumumab [17], erlotinib [15, 18, 37] and gefitinib [8, 38].”